Roche and Medicines Patent Pool Deal to Boost Access to Flu Drug

• Generic drugmakers can now develop, manufacture and supply Xofluza across 129 low- and middle-income countries under the licensing agreement
• Xofluza is WHO-recommended and approved in the US and Europe, showing effectiveness against flu strains resistant to older antiviral classes
• Roche will provide licenses with data packages, reference products and regulatory support to accelerate generic development, while manufacturers handle their own approval processes

Summary: Roche-Medicines Patent Pool Partnership Expands Flu Drug Access

Swiss pharmaceutical company Roche has signed a licensing agreement with the UN-backed Medicines Patent Pool (MPP) to expand access to its influenza treatment Xofluza in low- and middle-income countries (LMICs). Announced May 18, the deal covers 129 countries and aims to strengthen supply chains during seasonal flu outbreaks and potential pandemics.

Key Agreement Terms:

The partnership allows generic manufacturers to develop, produce, and distribute the antiviral pill across designated territories. Roche will provide licenses, data packages, reference products for bioequivalence studies, and regulatory support to accelerate generic development. Manufacturers will independently manage their own approval processes. The MPP will solicit expressions of interest from potential manufacturers.

Product Details:

Xofluza treats influenza in patients symptomatic for no more than two days. The drug has WHO recommendation and regulatory approval in the United States and Europe. Notably, it demonstrates effectiveness against flu strains resistant to older antiviral medications, positioning it as a critical outbreak management tool.

Market Context:

In October, Roche launched direct-to-consumer U.S. sales of Xofluza at a discounted $50 cash price, responding to Trump administration pressure to reduce prescription drug costs—a strategy mirrored by competitors.

Strategic Implications:

MPP Executive Director Charles Gore characterized the agreement as "public health-oriented," emphasizing preparedness for future health emergencies. The deal addresses significant treatment gaps in LMICs where flu medicine access remains limited, potentially creating substantial generic market opportunities while enhancing Roche's global health profile and pandemic preparedness positioning.